EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

Severe Evans Syndrome at the Infection–Inflammation–Autoimmunity Interface During Bacteriologically Confirmed Pulmonary Tuberculosis: A Case Report

Xueming Xie

Journal of Inflammation Research · 2026-10 · Volume 19 · 1-14

DOI: 10.2147/jir.s642564 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Inflammation Research, 2026-10. Verfasst von Xueming Xie. Beteiligte Einrichtung: Department of Infectious Diseases, Anshun People's Hospital, Anshun, Guizhou, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evans syndrome is a rare autoimmune cytopenia combining autoimmune hemolytic anemia and immune thrombocytopenia. Active pulmonary tuberculosis creates an inflammatory setting in which anemia of inflammation, bleeding, coagulation abnormalities, marrow involvement, and treatment toxicity can mimic or amplify cytopenia, making attribution to immune destruction difficult. Case Presentation: A 49-year-old man with smear-, Xpert MTB/RIF-, and culture-confirmed drug-susceptible post-primary pulmonary tuberculosis developed diffuse cutaneous bleeding, a hemoglobin nadir of 27 g/L, and a platelet nadir of 1×109/L. Warm autoimmune hemolysis was supported by a strongly positive direct antiglobulin test and a pan-reactive warm eluate with compatible hemolysis markers. The platelet component showed increased turnover, poor post-transfusion increments, and compensatory megakaryocytic hyperplasia. Because the glycoprotein-specific platelet-autoantibody assay was negative, immune thrombocytopenia remained a clinical diagnosis supported by the overall pattern and exclusion of major competing causes. Focused evaluation of an isolated APTT prolongation showed sustained correction on immediate and incubated mixing, no factor VIII, IX, or XI deficiency, no factor VIII inhibitor, and no significant anti-Xa activity. A separate flow-cytometric assay did not detect rifampicin-dependent platelet reactivity. Anti-tuberculosis therapy was continued while glucocorticoids, recombinant human thrombopoietin, transfusion support, and organ support were administered. Counts recovered during combined treatment, tuberculosis therapy was completed, and hematologic remission persisted for 12 months.

Conclusion

Severe infection-associated inflammation can coexist with and obscure autoimmune cytopenia. In this case, convergent evidence established warm autoimmune hemolysis, whereas the immune thrombocytopenia component was diagnosed clinically after exclusion of major competing explanations rather than by definitive platelet serology. The case supports a structured, parallel evaluation of infection, immune cytopenia, consumptive processes, marrow disease, and treatment-related causes without inferring that tuberculosis directly caused Evans syndrome. Evans syndrome is a rare condition in which the immune system destroys red blood cells and platelets. Tuberculosis and its treatment can also cause anemia, low platelets, bleeding, and inflammation, so identifying the main cause can be difficult. This report describes a man with laboratory-confirmed pulmonary tuberculosis whose hemoglobin fell to 27 g/L and platelet count to 1×109/L. Detailed testing demonstrated warm autoimmune hemolysis. The platelet findings showed rapid peripheral loss and preserved platelet production, but the standard platelet-autoantibody test was negative; therefore, immune thrombocytopenia was diagnosed clinically after other important causes were assessed. Additional hospital testing showed that the prolonged clotting test corrected when the patient’s plasma was mixed with normal plasma and did not reveal a major factor VIII, IX, or XI deficiency or a factor VIII inhibitor. A separate test did not detect a rifampicin-dependent platelet antibody. These findings made a major inhibitor and rifampicin-dependent immune thrombocytopenia less likely, although a negative drug-antibody test cannot exclude every drug-related mechanism. The patient received anti-tuberculosis treatment together with glucocorticoids, recombinant human thrombopoietin, blood-product transfusion, and supportive care. Both conditions improved, and the blood disorder remained in remission for 12 months. The case illustrates why severe cytopenia during an inflammatory infection requires specific evaluation rather than attribution to infection alone.

Schlagwörter

Stichwörter der Autor:innen

Evans syndromeautoimmune hemolytic anemiaimmune dysregulationimmune thrombocytopeniainflammationpulmonary tuberculosis

Autor:innen und Institutionen

  • Department of Infectious Diseases, Anshun People's Hospital, Anshun, Guizhou, People's Republic of China.

Zitieren

APA

Xie, X. (2026). Severe Evans Syndrome at the Infection–Inflammation–Autoimmunity Interface During Bacteriologically Confirmed Pulmonary Tuberculosis: A Case Report. Journal of Inflammation Research, Volume 19, 1-14. https://doi.org/10.2147/jir.s642564

Vancouver

Xie X. Severe Evans Syndrome at the Infection–Inflammation–Autoimmunity Interface During Bacteriologically Confirmed Pulmonary Tuberculosis: A Case Report. Journal of Inflammation Research. 2026;Volume 19:1-14. doi:10.2147/jir.s642564

BibTeX
@article{Xie2026,
  author = {Xie, Xueming},
  title = {Severe Evans Syndrome at the Infection–Inflammation–Autoimmunity Interface During Bacteriologically Confirmed Pulmonary Tuberculosis: A Case Report},
  journal = {Journal of Inflammation Research},
  year = {2026},
  volume = {Volume 19},
  pages = {1--14},
  doi = {10.2147/jir.s642564}
}
Kostenlos starten →